Eventide Gilead fund co-manager David Barksdale interviewed in ticker.com Q&A
The investment community site ticker.com has published a lengthy Q&A with Eventide Gilead Fund co-manager David Barksdale. Ticker.com subscribers can access the article online here: http://ticker.com/index.php?page=mutual_funds&id=921
In the interview, Barksdale gives an overview of Eventide Funds’ history, values, and investment philosophy, as well as outlining the funds’ approach to portfolio construction and risk management.
Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies normally have a lower trading volume than larger companies. The Fund’s ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.
Investors should carefully consider the investment objectives, risks, charges and expenses of the Eventide Gilead Fund. This and other important information about the Fund is contained in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). The prospectus should be read carefully before investing. The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC member FINRA.